Table 4.
Clinical predictors of 60 day all-cause mortality
| Survivors | Non-survivors | Unadjusted OR | p-value | Model 1 Adjusted OR |
p-value | Model 2 Adjusted OR | p-value | |
|---|---|---|---|---|---|---|---|---|
| Number | 115 | 39 | ||||||
| Median age (range) | 54 (18 – 79) |
55 (22 – 78) |
1.0 (0.99–1.04) | 0.31 | ||||
| Sex Female Male |
53 (46) 62 (54) |
12 (31) 27 (69) |
1.0 1.9 (0.9 – 4.2) |
0.10 |
|
|||
| Type of HCT HM without HCT Allogeneic-HCT Autologous HCT |
51 (44) 41 (36) 23 (20) |
18 (46) 16 (41) 5 (13) |
1.0 1.1 (0.5 – 2.4) 0.6 (0.2 – 1.9) |
0.80 0.39 |
1.0 3.7 (1.2 – 11.9) 1.6 (0.4 – 6.4) |
0.03 0.54 |
||
| Corticosteroids within 30 days No Yes |
49 (43) 66 (57) |
11 (28) 28 (72) |
1.0 1.7 (0.8 – 3.8) |
0.11 |
|
|||
| Neutropenia at RSV diagnosis No Yes |
89 (77) 26 (23) |
18 (46) 21 (54) |
1.0 4.0 (1.9 – 8.6) |
<0.001 |
1.0 8.3 (2.8 – 24.2) |
<0.001 |
||
| Lymphopenia at RSV diagnosis No Yes |
84 (73) 31 (27) |
16 (41) 23 (59) |
1.0 3.9 (1.8 – 8.3) |
<0.001 |
1.0 3.7 (1.7–8.2) |
0.001 |
||
| Type of LRTI Possible Proven |
104 (90) 11 (10) |
27 (69) 12 (31) |
1.0 4.2 (1.7–10.6) |
0.002 |
1.0 4.7 (1.7 – 13.5) |
0.004 |
1.0 3.3 (1.2–8.8) |
0.02 |
| Ribavirin therapy None URTI stage LRTI stage |
15 (13) 13 (11) 87 (76) |
8 (20) 1 (3) 30 (77) |
1.0 0.1 (0.01 – 1.1) 0.7 (0.3 – 1.7) |
0.09 0.37 |
1.0 0.1 (0.01 – 1.3) 0.6 (0.2– 1.9) |
0.08 0.43 |
1.0 0.2 (0.02, 1.5) 0.7 (0.2–1.8) |
0.10 0.43 |
Abbreviations: OR: odds ratio; HM: hematologic malignancy; HCT: hematopoietic stem cell transplant; RSV: respiratory syncytial virus; LRTI: lower respiratory tract infection; URTI: upper respiratory tract infection. Model 1 included neutropenia, but not lymphopenia, as a candidate variable for the final multivariate model, while Model 2 included lymphopenia, but not neutropenia.